New Crown Vaccine Five Questions: What step has it been developed? How long does it take to get vaccinated once?

With the new coronavirus vaccine research and development continue to make progress, in recent times, one after another out of the "vaccine is about to be approved for the market" "people have been vaccinated" and other news, there is no shortage of "in the short term difficult to achieve group immunization through the vaccine" "autumn and winter season new corona pneumonia and influenza may be superimposed" and other warning sounds.
interviewed authorities and professionals to answer questions about the new coronavirus vaccine of public concern.reporter learned from
joint prevention and control mechanism, China's four new coronavirus vaccine has opened the international Phase III. phase clinical trials, some trials will be completed in early September the first round of vaccination.
Phase III clinical trials are key studies to determine whether a vaccine can be approved for market, and will truly validate the safety and effectiveness of the vaccine, requiring thousands to tens of thousands of sample sizes. It is reported that the new coronavirus vaccine PHASE III clinical trials have been launched and preliminary data are expected to be available as soon as November.
Yang Xiaoming, chairman of China Biotechnology Co., Ltd., said that the two new coronavirus inactivated vaccines developed by the company have been approved in the Middle East, South America and other countries to carry out Phase III clinical trials, the total number of trials into the group of more than 30,000 people.
Weidong, chairman of Beijing Coxing Zhongwei Biotechnology Co., Ltd., said that a new coronavirus inactivated vaccine developed by the company is steadily advancing Phase III clinical trials in several countries in South America and Southeast Asia.
addition, the adenovirus
vector recombination new coronavirus vaccine developed by the Chen Wei team of the Military Academy of Military Medicine is also advancing the international Phase III. phase clinical trial in an orderly manner.
because the outbreak of neo-crown pneumonia is now effectively controlled in China, the domestic has no objective conditions for large-scale clinical trials, so the above-mentioned Phase III clinical trials are conducted overseas., according to Xu Jing, deputy director of the State Drug Administration, there are currently 5 technical routes, 10 new coronavirus vaccines have been approved for clinical trials.
is expected to be the first to cross the "finish line" of mass vaccination of the first four new coronavirus vaccine, respectively, belong to the inactivated vaccine, adenovirus vaccine two technical routes. The remaining three technical routes also include recombinant protein vaccines, anti-virus influenza virus vector vaccines, and nucleic acid vaccines.
, inactivated vaccines kill viruses by physical or chemical methods, but retain a vaccine that causes the virus to respond to human immune responses. Vaccines along this technical path have a longer-term research base.
adenovirus vaccine to the modified replication defective adenovirus as a carrier, carrying the new coronavirus S protein gene, into the subject's body, so that the human body produces immune memory, so as to achieve the virus "shut out" effect.
In addition, the new coronary recombinant protein vaccine, developed jointly by the China
Institute of Microbiology and Anhui Zhifeilong Koma Biopharmaceutical Co., Ltd., which is currently in Phase II clinical trials, is genetically engineered to express pure pathogen antigen proteins in engineered cells and then prepare them into a vaccine.
, regardless of the technical route of the vaccine, strict safety, effectiveness monitoring and evaluation will be in the first place. Under the premise of ensuring safe, effective and scientific compliance, the relevant enterprises will start large-scale vaccine production capacity.reporters from the
joint prevention and control mechanism was informed that China has approved on June 24 "new coronavirus vaccine emergency use (trial) program", approved two vaccines for emergency use, and on July 22 officially launched the emergency use of the new coronavirus vaccine.
Article 20 of the Vaccine Administration Law of the People's Republic of China, which has been in force since December 1, 2019, stipulates that in the event of a particularly serious public health emergency or other emergency that seriously threatens public health,
the competent department of health and health shall, in accordance with the need for the prevention and control of infectious diseases, make recommendations for the emergency use of the vaccine, which may be used urgently within a certain scope and within a certain period of time after the approval of the
Drug Administration.
are you getting an emergency vaccination? Zheng Zhongwei, director of the Science and Technology Development Center of the National Health and
Ance, said that according to relevant regulations, emergency use (trial) is limited to specific groups of people with high exposure risk and unable to use effective protective measures to implement protection; Special groups such as medical personnel, epidemic prevention personnel, border control personnel and basic urban operators are the objects of emergency vaccination, which can establish an immunization barrier and provide stable guarantee for social operation.
, it is understood that some overseas staff, as well as some medical personnel, market staff have also been urgently vaccinated against the new coronavirus inactivated vaccine. based on the results of the completed phase I. and II clinical trials, several new coronavirus vaccines show good safety and antibody effectiveness.
Yang Xiaoming said that two vaccines from Chinese biology were approved in April to start phase I. and II clinical trials, and the results showed that after two doses of the vaccine, the yang rate of the meso-antibodies reached 100%.
these antibodies last? The answer is still to be validated in Phase III clinical trials.
At the same time, a group of researchers is compiling data on cases of infection and rehabilitation during an outbreak in China, analyzing the sustained length of antibodies in their bodies, and trying to solve the question of "whether the new coronavirus will be infected twice".
According to the "Clinical Evaluation Guidelines (Trial) for New Coronavirus Prevention Vaccines" document issued recently by the Drug Audit Center of the State Drug Administration, the effectiveness of the new coronavirus vaccine is specifically proposed: vaccines are best provided for 1 year or more of protection, at least 6 months of protection. that the new coronavirus vaccine in the future is expected to achieve the season's influenza vaccine "two-in-one" to simplify the vaccination process.
before the new coronavirus vaccine was approved for sale, many experts called for greater vaccination of influenza vaccines to avoid the formation of new coronary pneumonia and influenza infectious diseases. wang Chen, president of
China Medicine
Beijing Concord Medical College, said that as the autumn and winter season approaches, once the new crown pneumonia is combined with influenza, it will be very difficult to identify the diagnosis, the difficulty of isolating the population will increase significantly, and the investment of social resources will increase significantly.
" is to get the flu vaccine in a timely and universal manner. Wang Chen said.